Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 09 2021
28 09 2021
Historique:
received:
22
12
2020
accepted:
11
08
2021
entrez:
29
9
2021
pubmed:
30
9
2021
medline:
28
12
2021
Statut:
epublish
Résumé
Schizophrenia (SZ) and major depressive disorder (MDD) are severe mental disorders, which have been associated with alterations of the peripheral inflammatory network. However, studies for both disorders have not been fully consistent and have focused on few canonical markers with high relevance to the innate immune system, while the role of the adaptive immune system is studied less. Furthermore, it is unclear to what extent inflammatory abnormalities are diagnosis-specific or transdiagnostic. The purpose of this study was to investigate 75 peripheral inflammatory markers including the acute phase protein high-sensitivity C-reactive protein (hsCRP) in patients with MDD (n = 37), SZ (n = 42) and healthy controls (HC) (n = 17), while considering possible confounders and correcting rigorously for multiple testing in group comparisons. We identified C-C chemokine ligand 20 (CCL20) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as the inflammatory markers with significant group differences after controlling for multiple comparisons and adjusting for BMI, sex and smoking as confounders. TRAIL was elevated in both MDD and SZ compared to HC. CCL20 was specifically increased in SZ compared to MDD and HC. There were no significant group differences in hsCRP after correcting for multiple testing. Finally, we observed no significant correlations among CCL20, TRAIL and CRP. TRAIL is a transdiagnostic marker for SZ and MDD, with both markers being independent from CRP and body mass index (BMI). CCL20 may be a novel and specific biomarker of schizophrenia, but an influence of antipsychotic medication cannot be excluded. Identifying novel markers in mental disease bears the potential for future research towards novel treatment strategies by modifying inflammation-related processes.
Identifiants
pubmed: 34584171
doi: 10.1038/s41598-021-98769-0
pii: 10.1038/s41598-021-98769-0
pmc: PMC8479067
doi:
Substances chimiques
Biomarkers
0
CCL20 protein, human
0
Chemokine CCL20
0
TNF-Related Apoptosis-Inducing Ligand
0
TNFSF10 protein, human
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19204Informations de copyright
© 2021. The Author(s).
Références
Brain Behav Immun. 2013 Jul;31:90-5
pubmed: 22749891
Brain Behav Immun. 2018 Oct;73:85-114
pubmed: 29928963
PLoS One. 2016 Mar 30;11(3):e0150464
pubmed: 27028512
Front Psychiatry. 2018 Aug 23;9:392
pubmed: 30190688
Cell Mol Life Sci. 2016 May;73(10):2017-27
pubmed: 26910728
Biol Psychiatry. 2010 Mar 1;67(5):446-57
pubmed: 20015486
Front Psychiatry. 2019 Jan 31;9:753
pubmed: 30766494
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jun;29(5):846-58
pubmed: 15908096
Pharmacol Ther. 2011 May;130(2):226-38
pubmed: 21334376
Neuropathol Appl Neurobiol. 2010 Apr;36(3):168-82
pubmed: 20102513
J Affect Disord. 2015 Jul 15;180:179-84
pubmed: 25911132
Transl Psychiatry. 2014 Feb 25;4:e365
pubmed: 24569695
Mol Psychiatry. 2015 Feb;20(1):84-97
pubmed: 25048005
Transl Psychiatry. 2020 Sep 1;10(1):304
pubmed: 32873782
Sci Rep. 2021 May 11;11(1):9992
pubmed: 33976271
Brain Behav Immun. 2018 Oct;73:163-164
pubmed: 30077590
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jun 3;67:51-7
pubmed: 26780170
Biomark Insights. 2010 May 12;5:39-47
pubmed: 20520744
Semin Immunopathol. 2015 Nov;37(6):625-38
pubmed: 26223505
Int J Biochem Cell Biol. 2018 Jun;99:169-177
pubmed: 29635023
Psychiatry Res. 2018 Nov;269:517-523
pubmed: 30195746
Brain Behav Immun. 2001 Dec;15(4):340-70
pubmed: 11782103
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 30;86:89-94
pubmed: 29778547
Mol Psychiatry. 2012 May;17(5):494-502
pubmed: 21483431
Biol Psychiatry. 2011 Oct 1;70(7):663-71
pubmed: 21641581
Mediators Inflamm. 2001 Jun;10(3):109-15
pubmed: 11545247
Schizophr Res. 2006 Jan 1;81(1):47-63
pubmed: 16226876
Mol Psychiatry. 2016 Dec;21(12):1696-1709
pubmed: 26903267
J Affect Disord. 2013 Sep 25;150(3):736-44
pubmed: 23870425
Biol Psychiatry. 2008 Nov 1;64(9):820-2
pubmed: 18534557
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:295-303
pubmed: 23313563
Mol Psychiatry. 2020 Jun;25(6):1301-1311
pubmed: 29895893
Neurosci Biobehav Rev. 2016 May;64:83-100
pubmed: 26898639
J Affect Disord. 2010 Jan;120(1-3):245-8
pubmed: 19446343
Brain Behav Immun. 2020 Jul;87:634-644
pubmed: 32109548
J Nucl Med. 2009 Nov;50(11):1801-7
pubmed: 19837763
Schizophr Res. 2015 Oct;168(1-2):456-60
pubmed: 26341579
Arch Gen Psychiatry. 2008 Apr;65(4):395-407
pubmed: 18391128
Front Immunol. 2020 Jan 17;10:2971
pubmed: 32010121
Psychiatry Res. 2008 Sep 30;160(3):256-62
pubmed: 18722671
Compr Psychiatry. 2013 Oct;54(7):953-61
pubmed: 23639406
Nat Med. 2007 Nov;13(11):1308-15
pubmed: 17934471
Front Neurosci. 2018 Aug 17;12:547
pubmed: 30174579
Transl Psychiatry. 2019 Sep 18;9(1):233
pubmed: 31534116
J Med Dent Sci. 2003 Mar;50(1):17-25
pubmed: 12715915
Brain Behav Immun. 2009 Oct;23(7):887-97
pubmed: 19389469
J Psychiatr Res. 2021 Aug;140:141-148
pubmed: 34116440
Schizophr Res. 2013 Dec;151(1-3):29-35
pubmed: 24210870
PLoS One. 2010 Feb 11;5(2):e9166
pubmed: 20161799
Brain Behav Immun. 2020 Jul;87:901-909
pubmed: 32113908
Front Immunol. 2013 Jul 15;4:194
pubmed: 23874340
Immunology. 2017 Nov;152(3):388-401
pubmed: 28704576
Psychoneuroendocrinology. 2012 Dec;37(12):1901-11
pubmed: 22541717
Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79
pubmed: 21896369
Exp Biol Med (Maywood). 2015 Jun;240(6):760-73
pubmed: 25854879
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jul 13;85:136-151
pubmed: 28803923
Nat Rev Rheumatol. 2011 May;7(5):282-9
pubmed: 21468143
Psychiatry Res. 2021 Mar;297:113745
pubmed: 33524773
Arch Immunol Ther Exp (Warsz). 2001;49(6):439-45
pubmed: 11814238
Nat Immunol. 2009 May;10(5):453-5
pubmed: 19381137
BMC Neurosci. 2011 Jan 25;12:13
pubmed: 21266029
Biol Psychiatry. 2019 Sep 15;86(6):410-420
pubmed: 31178098
Lancet Psychiatry. 2018 Jan;5(1):79-92
pubmed: 28781208
Psychopharmacology (Berl). 2016 May;233(9):1575-89
pubmed: 26268146
Neurol Clin. 2006 Aug;24(3):507-19
pubmed: 16877121
J Psychiatr Res. 2014 Jun;53:180-6
pubmed: 24631195
NPJ Schizophr. 2021 Feb 3;7(1):6
pubmed: 33536449
Obes Rev. 2019 Dec;20(12):1680-1690
pubmed: 31524318